# An individualized prognostic nomogram integrating clinical and pathological features in pediatric IgA vasculitis nephritis

## TL;DR

A new tool was created to predict kidney function decline in children with IgA vasculitis nephritis using clinical and biopsy data.

## Contribution

Development of a validated individualized prognostic nomogram for pediatric IgA vasculitis nephritis.

## Key findings

- The nomogram includes five predictors like male sex and IgA deposits to estimate risk.
- The model showed strong discrimination with a C-index of 0.796 in validation.
- High-risk patients had significantly worse event-free survival.

## Abstract

To develop and validate an individualized prognostic nomogram integrating clinical and pathological features for estimating the risk of renal function decline in children with IgA vasculitis nephritis (IgAVN).

In this single-center retrospective cohort, 603 children with biopsy-confirmed IgAVN and ≥12 months of follow-up were included. The primary endpoint was a composite of eGFR <90 mL/min/1.73 m2 or a ≥ 30% decline from baseline, first occurring after 12 months of follow-up. The cohort was randomly split into training (80%) and validation (20%) sets. Variable selection was performed using elastic-net regression with five-fold cross-validation, followed by backward stepwise Cox proportional hazards modelling.

Over a median follow-up of 48.7 months (IQR: 28.5–73.3 months), 68 patients (11.3%) reached the endpoint. The final model identified five independent predictors: male sex (HR = 2.12), renal IgA deposit 3+ (HR = 2.66), ISKDC grade IV–VI (HR = 4.63), Oxford T1/2 lesions (HR = 4.72), and baseline serum creatinine. The model showed strong and consistent discrimination in the validation set (C-index = 0.796; 60 month AUC = 0.859; 84 month AUC = 0.850), adequate calibration, and provided positive net clinical benefit on decision curve analysis. A practical nomogram was developed for risk estimation. Kaplan-Meier analysis demonstrated significantly lower event-free survival in the high-risk group (log-rank p < 0.001).

We successfully developed and validated an individualized prognostic nomogram. This tool integrates key clinical and pathological features to quantify the risk of renal function decline in children with IgAVN shortly after renal biopsy, providing a basis for personalized management decisions.